DONATE TODAY
To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

February 29, 2024

A Message from Our CEO: Help DCVax®-L Gain FDA Approval

NWBio Logo

The End Brain Cancer Initiative and I know and understand this disease well. We know that to increase survival of this disease, patients must have full access to FDA approved treatments and they need to have as many treatment options available to them as possible. DCVax®-L is one of the treatment options/tools that patients should have in their toolbox.

The FDA needs to understand that not one treatment is viable for this disease as Glioblastoma (GBM) quickly becomes resistant to all treatment. Therefore, patients need to have multiple and varied treatment options so that when their tumor becomes resistant to a treatment, they are able to quickly pivot. In order to provide brain cancer patients multiple treatment options, increase patient Quality of Life, provide HOPE for this patient community, and encourage additional investment by the pharma/biotech companies into GBM research, the FDA needs to approve multiple treatment options for this patient population. Currently, there are a very limited number of treatment options FDA approved for this disease. EBCI and I are working very hard to expand access to treatment options and to improve Standard of Care for the brain tumor community.

Team up with the End Brain Cancer Initiative to help DCVax®-L gain FDA approval by clicking the button below.

DCVax®-L represents a novel form of immunotherapy classified as a dendritic cell vaccine. Developed by Northwest Biotherapeutics, this personalized vaccine is crafted from each patient’s unique dendritic cells, a crucial component aiding the immune system in recognizing and combatting cancer cells. The intricate process involves isolating immune cells from the patient’s blood, exposing them to tumor cells, and enabling dendritic cells to recognize specific markers associated with the patient’s tumor cells. Once re-introduced into the patient’s system, these “educated” dendritic cells recruit and instruct other immune cells, known as T-cells, to travel to the tumor site and attack cancerous cells.

Team up with the End Brain Cancer Initiative to help DCVax®-L gain FDA approval by clicking the button below.

Dellann Secondary Headshot 2024

Dellann Elliott Mydland
The End Brain Cancer Initiative
President & CEO

Dellann@EndBrainCancer.org
425-436-8688

ebci logo

Hand holding cell phone displaying app
  • Trials & Studies
  • New Research
  • Patient & Caregiver Resources
  • Disease Information
  • Meetings & Events
  • And More!
EBCI App QR

Scan or click the QR code to download the App now!


Sponsor logos

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
DONATE
corporate partners
upcoming events
resources
About us
envelopephonemap-markerpointer-right
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram